Diabetes Care, Vol 18, Issue 12 1577-1581, Copyright © 1995 by American Diabetes Association

ARTICLES

Fibrinolysis and diabetic retinopathy in NIDDM

MW Mansfield and PJ Grant
Division of Medicine, University of Leeds, U.K. michaelm@pathology.leeds.ac.uk

OBJECTIVE: By contributing to a prothrombotic state, increased levels of plasminogen activator inhibitor-1 (PAI-1) may be involved in the pathogenesis of the vascular complications of non-insulin-dependent diabetes mellitus (NIDDM). The objective of this study was to compare levels of components of the fibrinolytic system in NIDDM subjects with and without retinopathy. RESEARCH DESIGN AND METHODS: A total of 135 Caucasian NIDDM subjects treated with oral therapy or diet alone were classified by the presence or absence of retinopathy, and fasting blood samples were taken for assay of PAI-1 antigen and activity, tissue plasminogen activator (t-PA), t-PA complexed with PAI-1, euglobulin clot lysis time (a measure of overall fibrinolytic activity), glucose, HbA1c, cholesterol, triglyceride, and insulin levels. RESULTS: Subjects with retinopathy had a longer disease duration than those without (9 vs. 5 years, P < 0.0001) and had lower levels of PAI-1 (PAI-1 antigen) (geometric mean and 95% confidence interval), 13.9 (10.4-18.6) vs. 24.1 (21.2-27.4) ng/ml (P < 0.0005); t-PA antigen, 9.6 (8.6-10.7) vs. 11.5 (10.8-12.3) ng/ml (P < 0.01); t-PA--PAI-1 complexes, 6.2 (5.2-7.2) vs. 7.8 (6.8-8.8) ng/ml (P < 0.05); and insulin, 11.5 (9.3-14.3) vs. 19.5 (17.0-22.3) mU/l (P < 0.0005). Euglobulin clot lysis time was shorter in the subjects with retinopathy, 273 (238-312) vs. 327 (303-352) min. When entered into a logistic regression model, disease duration, PAI-1 antigen, and HbA1c remained as significant independent associates of the presence of retinopathy. CONCLUSIONS: These results do not support the hypothesis that impaired fibrinolysis due to elevated PAI-1 is associated with the development of retinopathy because fibrinolysis is indeed enhanced and PAI-1 lower in subjects with retinopathy.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Emanuele, J. Sacks, R. Klein, D. Reda, R. Anderson, W. Duckworth, C. Abraira, and for the Veterans Affairs Diabetes Trial Group Ethnicity, Race, and Baseline Retinopathy Correlates in the Veterans Affairs Diabetes Trial Diabetes Care, August 1, 2005; 28(8): 1954 - 1958. [Abstract] [Full Text] [PDF]

				C. Giusti, R. Schiaffini, C. Brufani, A. Pantaleo, E. M. Vingolo, and P. Gargiulo Coagulation pathways and diabetic retinopathy: abnormal modulation in a selected group of insulin dependent diabetic patients Br. J. Ophthalmol., June 1, 2000; 84(6): 591 - 595. [Abstract] [Full Text]

				C. Giusti, R. Schiaffini, D. Bosco, P. Ciampalini, A. Pantaleo, E. M Vingolo, and P. Gargiulo Lupus anticoagulant positivity in insulin dependent diabetic patients: an additional risk factor in the pathogenesis of diabetic retinopathy? Br. J. Ophthalmol., May 1, 2000; 84(5): 531 - 533. [Abstract] [Full Text]